Long-term treatment with zimelidine leads to a reduction in 5-hydroxytryptamine neurotransmission within the central nervous system of the mouse and rat.
Male rats and mice received a 14 day peroral treatment with zimelidine, a novel antidepressant drug. Zimelidine produced a 70 and 60% reduction in the number of high affinity [3H]5-hydroxytryptamine (5-HT) and [3H]D-lysergic acid diethylamide (LSD) binding sites, respectively, and induced low affinity binding sites for [3H]5-HT and for [3H]D-LSD. The head twitch behaviour induced by 5-hydroxytryptophan and 5-methoxydimethyltryptamine was attenuated and reductions of prolactin and growth hormone were observed. These findings give further evidence that long-term treatment with zimelidine can produce a reduction of 5-HT neurotransmission in several brain regions.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001665:Binding Sites; D001921:Brain / Q000187:drug effects*; D001977:Brompheniramine / Q000031:analogs & derivatives / Q000494:pharmacology*; D007700:Kinetics; D008238:Lysergic Acid Diethylamide / Q000378:metabolism; D008297:Male; D051379:Mice; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects; D013997:Time Factors; D015031:Zimeldine
D000928:Antidepressive Agents; D011725:Pyridines; D011985:Receptors, Serotonin; D012701:Serotonin; D015031:Zimeldine; D008238:Lysergic Acid Diethylamide; D001977:Brompheniramine